Table 2.
Base material | Main compounds/agents | Mode of action | Ref. |
Probiotics | |||
Lactic acid bacteria | Lactobacillus suntoryeus | Inhibited the activation of TLR-4-linked NF-κB activation | [32] |
Lactococcus lactis subsp. lactis S-SU2 | Prevented the colonic shortening, lowering of liver and thymus weights, and spleen enlargement | [33] | |
Lactobacillus paracasei LS2 (from kimchi) | Increased IL-10 | [34] | |
Reduced TNF-α, IFN-γ, IL-1β and MPO activity | |||
Lactococcus lactis NZ9000 (NZ-HO) | Reduced CD11b+ F4/80+ and CD11b+ Gr-1+ | [35] | |
Lactobacillus plantarum AN1 | Increased IL-10; reduced IL-1α and IL-6 | [36] | |
Lactobacillus sakei K040706 | Ameliorated the atrophy of colon length, mucosal damage, and spleen enlargement | [38] | |
Bifidobacteria | Bifidobacterium bifidum 231 | Reduced the expression of iNOS, TNF-α, IL-1β, and IL-6 | [41] |
Bifidobacterium longum CCM7952 | Suppressed NF-κB, STAT3, and TLR4 expression | [31] | |
Increased IL-10; Decreased IL-1β | |||
Engaged TLR2; Contained NOD2 | |||
Improved epithelial barrier | |||
Dietary fibers and prebiotics | |||
Konjac glucomannan | Konjac glucomannan hydrolysate | Reduced bowel movement, diarrhea, blood in feces, abdominal pain, and flatulence | [44] |
Glucan | β-(1,3–1,6)-d-glucan | Improved fecal output | [45] |
Oat β-glucan | Reduced visceral pain | [46] | |
Lowered MPO, NO, and MDA | |||
Inhibited the expressions of TNF-α, IL-1β, IL-6 and iNOS | |||
Glucan from mushroom (Pleurotus pulmonarius) | Reduced histological damage | [47] | |
Bacterial β-(1,3)-glucan | Reduced the expression of IL-1β | [48] | |
Reversed Treg reduction | |||
Nanofiber | Cellulose nanofiber from seaweed | Decreased NK cell defects and IgA production | [49] |
Prebiotics | Cellulose nanofiber from pear | Improved intestinal tissue injury | [50] |
Suppressed the activation of NF-κB | |||
Fructooligosaccharides | Suppressed colon atrophy | [51] | |
Suppressed the activation of NF-κB | |||
Goat milk oligosaccharide | Decreased IFN-γ, IL-17, and TNF-α levels | [52] | |
Inulin | Increased LAB population | [53] | |
Decreased inflammation | |||
Improved mucosal damage | |||
Decreased TNFα, COX-2, IL-2, and IL-6 | |||
Vitamins | 1alpha,25-dihydroxyvitamin D3 | Suppressed TNF-α | [57] |
Enhanced IL-10 production | |||
1,25-dihydroxyvitamin D3 | Reduced IFN-γ | [58] | |
Vitamin D3 | Increased CD+ T cells and IL-6 | [59] | |
Protected mitochondria | |||
Vitamin A | Inhibited nuclear respiratory factor (NFR)-1 and mitochondrial transcription factor A (TFAM) | [60] |
TLR: Toll-like receptor; TNF-α: Tumor necrosis factor α; IFN-γ: Interferon γ; IL: Interleukin; NF-κB: Nuclear factor κB.